Reporting
Inflammation
Vaccines and Immunotherapies (VIT)
Filter By:
Terminated
CTNPT 022A: PROOV IT I
Probiotic Visbiome for Inflammation and Translocation in HIV (PROOV IT I)
Learn MoreReporting
CTNPT 021: The (BATARI) Pilot Trial
Bone Antiresorptive Therapy with AntiRetroviral Initiation (BATARI) Pilot Trial
Learn MoreCompleted
CTN 020: Itraconazole, ketoconazole
Clinical Evaluation of Itraconazole vs. Ketoconazole in HIV+ Patients with Oropharyngeal and/or Oesophageal Candidiasis
Learn MoreTerminated
CTNPT 020: Therapeutic HIV vaccine with early HAART treatment initiation
A pilot randomized, open label study to evaluate the effect of a therapeutic HIV vaccine consisting of PENNVAX®-GP (gag, pol, env) and INO-9012 DNA vaccine delivered via electroporation on reducing HIV viral reservoirs in infected individuals, who initiated therapy during the acute/early phase of infection
Learn MoreTerminated
CTNPT 019: Improving outcomes with Metformin
Can metformin prevent the progression of liver fibrosis in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance?
Learn MoreCompleted
CTNPT 017: Valacyclovir for Inflammation Attenuation Trial Pilot (VALIANT Pilot)
Can valacylovir attenuate inflammation in ART-treated HIV-infected individuals with herpes simplex virus type 2? Trial results
Learn MoreReporting
CTNPT 016: Herpesvirus shedding among HIV inpatients
Assessing feasibility of collecting repeated blood and swab samples for herpesviruses in HIV-infected individuals hospitalized with acute illness
Learn MoreCompleted
CTN 016: Acemennan
A Pilot Controlled Double Blind Study of Acemennan in Patients Receiving AZT for the Treatment of Advanced HIV Disease
Learn More
CTN Trials have been approved by the Community Advisory Committee of the Canadian HIV Trials Network and the Network’s Scientific Review Committee, or other national peer-review panels such as those at the Canadian Institutes of Health Research and the U.S. National Institutes of Health. CTNPT studies are small-scale investigations designed to determine the feasibility of research concepts, and do not all go through the regular CTN clinical trial review process. For information on the benefits and risks of participating in HIV clinical trials, call CATIE toll-free at 1-800-263-1638.